132658Generation of Small Molecule Asthma Disease Modifying Agents from a TB Derived Peptide LeadClosedFeasibility StudiesInnovate UKPeptinnovate is a drug discovery and development company based in the Stevenage Bioscience Catalyst on the GSK site. The company's core research is based on molecules derived from Mycobacterium tuberculosis proteins as innovative immunomodulatory agents for the treatment of chronic inflammatory diseases. The lead molecule PIN201104 is an extremely safe, low molecular weight peptide identified by phenotypic drug discovery in collaboration with a number of leading UK academic groups. PIN201104 is being progressed into the clinic as a first in class disease modifying agent for the treatment of asthma and other chronic inflammatory conditions. Peptinnovate through this grant will exploit the disease modifying approach it has identified for PIN201104 to generate small molecule analogues. Further modification of these analogues subsequent to this project will allow the generation of orally active disease modifying agents for the treatment of mild to moderate asthmatics. There are currently no disease modifying agents available for the treatment of asthma. Peptinnovate is pioneering the discovery of agents with the potential to change the underlying disease of chronic inflammatory asthma and lead to potential curative therapies.